Aytu Biopharma, Inc
AYTU- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001385818
No open-market purchases or sales by Aytu Biopharma, Inc insiders were filed in the last 90 days; 38 institutions reported holding it in 13F filings for Q2 2026, worth $8.25M in total; no superinvestor holds it.
13F holders, Q3 2024
Institutional positions in Aytu Biopharma, Inc as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 24
- −2 vs. Q2 2024
- Shares held
- 2.05M
- +17.3K (+0.9%) vs. Q2 2024
- Total value
- $4.81M
- −$1.12M (−18.8%) vs. Q2 2024
- New holders
- 1
- 4 more added
- Sold out
- 3
- 7 more reduced
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AYTU on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 38 | $8.25M |
| Q1 2026 | 37 | $10.7M |
| Q4 2025 | 39 | $9.81M |
| Q3 2025 | 33 | $6.73M |
| Q2 2025 | 32 | $7.45M |
| Q1 2025 | 31 | $2.49M |
| Q4 2024 | 29 | $3.19M |
| Q3 2024 | 24 | $4.81M |
| Q2 2024 | 27 | $5.99M |
| Q1 2024 | 27 | $5.46M |
| Q4 2023 | 22 | $5.02M |
| Q3 2023 | 22 | $4.65M |
| Q2 2023 | 21 | $2.73M |
| Q1 2023 | 21 | $1.21M |
| Q4 2022 | 42 | $1.52M |
| Q3 2022 | 53 | $1.64M |
| Q2 2022 | 41 | $2.50M |
| Q1 2022 | 44 | $6.02M |
| Q4 2021 | 46 | $5.10M |
| Q3 2021 | 49 | $12.2M |
| Q2 2021 | 61 | $26.0M |
| Q1 2021 | 72 | $48.4M |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Aytu Biopharma, Inc; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 1,086,812 | $2.55M | 0.21% | 00.0% | Unchanged |
| Stonepine Capital Management, LLC | 500,958 | $1.18M | 0.74% | +28,489+6.0% | Added |
| Armistice Capital, LLC | 236,000 | $554.6K | 0.01% | −16,000−6.3% | Reduced |
| Renaissance Technologies LLC | 74,723 | $175.6K | 0.00% | +600+0.8% | Added |
| Geode Capital Management, LLC | 45,102 | $106.0K | 0.00% | +9,183+25.6% | Added |
| Vanguard Group Inc | 27,888 | $65.5K | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 22,793 | $53.6K | 0.00% | +22,793 | New |
| Dimensional Fund Advisors LP | 21,832 | $51.3K | 0.00% | −1,719−7.3% | Reduced |
| Northern Trust Corp | 14,557 | $34.2K | 0.00% | 00.0% | Unchanged |
| Acadian Asset Management LLC | 14,622 | $34.0K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 1,473 | $3.46K | 0.00% | −489−24.9% | Reduced |
| JPMorgan Chase & Co | 313 | $736 | 0.00% | −227−42.0% | Reduced |
| Advisor Group Holdings, Inc. | 300 | $705 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 290 | $681 | 0.00% | −150−34.1% | Reduced |
| UBS Group AG | 260 | $611 | 0.00% | −48−15.6% | Reduced |
| Wells Fargo & Company | 124 | $291 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 98 | $231 | 0.00% | +6+6.5% | Added |
| CIBC Private Wealth Group, LLC | 83 | $195 | 0.00% | 00.0% | Unchanged |
| Group One Trading, L.P. | 37 | $87 | 0.00% | 00.0% | Unchanged |
| GWM Advisors LLC | 21 | $49 | 0.00% | 00.0% | Unchanged |
| SJS Investment Consulting Inc. | 5 | $12 | 0.00% | 00.0% | Unchanged |
| CarsonAllaria Wealth Management, Ltd. | 5 | $12 | 0.00% | 00.0% | Unchanged |
| US Bancorp | 3 | $7 | 0.00% | −6−66.7% | Reduced |
| TSFG, LLC | 1 | $0 | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −21,810−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −3,285−100.0% | Sold out |
| Huntington National Bank | 0 | $0 | 0.00% | −20−100.0% | Sold out |
| BlackRock Inc. | – | – | – | – | Not filed |